About Verdemed
Verdemed strives to bring cannabis-based medications to patients in Latin America.
Cannabis has been used as a health treatment throughout most of human history. A number of cultures have taken advantage of its medical properties, and, over the past two decades, the scientific community has increasingly identified these medical attributes.
There are hundreds of peer-reviewed scientific studies recognizing the potential of cannabis-based pharmaceuticals to substantially improve many health conditions. Verdemed’s mission is to realize this potential in Latin America by bringing cutting-edge medication to this area and enabling doctors to improve the treatment of millions of patients.
Verdemed brings affordable cannabinoid-based pharmaceuticals to doctors and patients in Latin America
Verdemed’s mission is to offer the best of approved existing and prospective cannabinoid products to all Latin Americans, in all countries and in all jurisdictions legally authorized to sell medical cannabis.
The company’s focus is on product formulations of cannabinoid pharmaceuticals currently available in Canada, Europe, and the USA. Verdemed aims to meet Latin America’s medical needs with similar products and medical cannabis treatments approved by Health Canada, EMA (European Medicines Agency), and the USA FDA (Food and Drug Administration).
Verdemed is uniquely positioned to tackle the high regulatory hurdles in Latin America with Canadian-derived pharmaceutical products.
Over the past 20 years, Canada has built a robust regulatory framework to protect patients’ safety and to secure reliable treatments with medical cannabis products. Today most Latin American regulatory agencies have in place a regulatory regime similar to Canadian legislation around medical cannabis.
Operations
What We Do
Verdemed is a Canadian pharmaceutical cannabis company whose goal is to improve the health of millions of patients in Latin America.
Based in Toronto, Canada, Verdemed’s multi-level and multi-market approach aims to bridge the gap between the European and North American cannabis pharmaceutical landscape and Latin American unmet clinical needs.
The company’s international footprint provides strategic access to market innovations, as well as well-known proven cannabis therapies. Verdemed plans to introduce to Latin America an ample range of cannabinoid-based medications in the next few years, fully approved by the principal regulatory agencies in the region – such as ANMAT, Anvisa, COFEPRIS, DIGEMID, Invima, and ISP.
Verdemed will start with CBD-based products in late 2019 and THC/CBD products in early 2020, based on pharmaceutical clinical trials and outcomes already approved in other countries around the world.
Medicinal Cannabis vs. Cannabinoid-Based Pharmaceuticals
Latin America Partner of Choice for Global Cannabis Pharmaceutical Companies
Verdemed aspires to become the platform of choice for global innovators entering the Latin American market with new medical cannabis products. The company is building strategic alliances and partnerships with global cannabis pharmaceutical companies to achieve this goal.
Verdemed will leverage its Canadian base and international presence to bring to Latin America pure pharmaceutical cannabinoid-based products that are currently in clinical trials around the world.
Verdemed also plans to conduct clinical trials in the larger Latin American countries with its partners involving proprietary formulations. The company will put innovative new products through the traditional pharmaceutical drug development approval process.
Verdemed will ensure that it offers only proven safe pharmaceutical products to doctors and patients in the region.
Line of Products
2019/2021
CBD gel capsules (5/10/20mg) – proprietary formulation
CBD oral solution – similar formulation and presentation of Epidiolex - CBD
THC/CBD gel capsules for insomnia clinical trials – proprietary formulation
THC/CBD mouth spray – similar formulation and presentation of Sativex - nabiximol
THC gel capsules – (2.5/5/10mg) – similar formulation and presentation of dronabinol from plant-based extracts
Later in 2021 – after the completion of Verdemed’s clinical trials in Argentina, Brazil, Chile, Colombia, Mexico, and Peru, the company plans to offer products for other conditions, such as chronic pain, glaucoma, and social anxiety.
Verdemed’s product pipeline includes over ten different indications for clinical trials over the next five to seven years.